Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francis Giles

Showing results (41-50 of 174) with videos related to

Pageof 18
Sort By:
Leukemia Research|April 12, 2003
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemiaSrdan Verstovsek, Scott Lunin, Hagop Kantarjian, et al.
Leukemia & Lymphoma|June 20, 2007
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring SystemMiloslav Beran, Sijin Wen, Yu Shen, et al.
Leukemia Research|May 30, 2006
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapseJoseph Moore, Karen Seiter, Jonathan Kolitz, et al.
Hematology/Oncology Clinics of North America|July 24, 2004
Investigational strategies in chronic myelogenous leukemiaJorge E Cortes, Susan M O'Brien, Francis Giles, et al.
Journal for Immunotherapy of Cancer|May 18, 2018
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)Young Kwang Chae, Ayush Arya, Wade Iams, et al.
Current Drug Targets|July 23, 2011
The Pim kinases: new targets for drug developmentRonan Swords, Kevin Kelly, Jennifer Carew, et al.
Clinical Lung Cancer|August 14, 2016
Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung CancerYoung Kwang Chae, Alan Pan, Andrew A Davis, et al.
Cancer|March 17, 2007
The incidence and impact of thrombocytopenia in myelodysplastic syndromesHagop Kantarjian, Francis Giles, Alan List, et al.
Blood|September 23, 2006
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureAlfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, et al.
Leukemia Research|March 22, 2003
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AMLElihu Estey, Francis Giles, Jorge Cortes, et al.
Pageof 18

Showing results (41-50 of 174) with videos related to

Sort By:
Pageof 18
Leukemia Research|April 12, 2003
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemiaSrdan Verstovsek, Scott Lunin, Hagop Kantarjian, et al.
Leukemia & Lymphoma|June 20, 2007
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring SystemMiloslav Beran, Sijin Wen, Yu Shen, et al.
Leukemia Research|May 30, 2006
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapseJoseph Moore, Karen Seiter, Jonathan Kolitz, et al.
Hematology/Oncology Clinics of North America|July 24, 2004
Investigational strategies in chronic myelogenous leukemiaJorge E Cortes, Susan M O'Brien, Francis Giles, et al.
Journal for Immunotherapy of Cancer|May 18, 2018
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)Young Kwang Chae, Ayush Arya, Wade Iams, et al.
Current Drug Targets|July 23, 2011
The Pim kinases: new targets for drug developmentRonan Swords, Kevin Kelly, Jennifer Carew, et al.
Clinical Lung Cancer|August 14, 2016
Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung CancerYoung Kwang Chae, Alan Pan, Andrew A Davis, et al.
Cancer|March 17, 2007
The incidence and impact of thrombocytopenia in myelodysplastic syndromesHagop Kantarjian, Francis Giles, Alan List, et al.
Blood|September 23, 2006
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureAlfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, et al.
Leukemia Research|March 22, 2003
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AMLElihu Estey, Francis Giles, Jorge Cortes, et al.
Pageof 18